Search Results - "Angus, Peter"

The role of the gut microbiota in NAFLD by Leung, Christopher, Rivera, Leni, Furness, John B., Angus, Peter W.

“…Key Points The incidence of fatty liver disease, and its complications of inflammation, fibrosis and liver cancer, is increasing Gut dysbiosis (an unhealthy…”
Get full text

Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial by Sinclair, Marie, Grossmann, Mathis, Hoermann, Rudolf, Angus, Peter W, Gow, Paul J

“…Graphical abstract…”
Get full text

Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products by Fernando, Dinali H, Forbes, Josephine M, Angus, Peter W, Herath, Chandana B

“…Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of the adult population and is now a major cause of liver disease-related premature illness and…”
Get full text

Testosterone in men with advanced liver disease: Abnormalities and implications by Sinclair, Marie, Grossmann, Mathis, Gow, Paul J, Angus, Peter W

“…Serum testosterone is reduced in up to 90% of men with cirrhosis, with levels falling as liver disease advances. Testosterone is an important anabolic hormone,…”
Get full text

Cirrhotic portal hypertension: From pathophysiology to novel therapeutics by Gunarathne, Lakmie S, Rajapaksha, Harinda, Shackel, Nicholas, Angus, Peter W, Herath, Chandana B

“…Portal hypertension and bleeding from gastroesophageal varices is the major cause of morbidity and mortality in patients with cirrhosis. Portal hypertension is…”
Get full text

Handgrip Strength Adds More Prognostic Value to the Model for End‐Stage Liver Disease Score Than Imaging‐Based Measures of Muscle Mass in Men With Cirrhosis by Sinclair, Marie, Chapman, Brooke, Hoermann, Rudolf, Angus, Peter W., Testro, Adam, Scodellaro, Thomas, Gow, Paul J.

“…Sarcopenia is associated with mortality in cirrhosis, but there is no gold standard for its diagnosis. The comparative utility of different diagnostic methods…”
Get full text

Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis by Carbone, Laura J, Angus, Peter W, Yeomans, Neville D

“…Background and Aim: Non‐alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease in Western societies. Despite its significance, there…”
Get full text

Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease by Leung, Christopher, Yeoh, Sern Wei, Patrick, Desmond, Ket, Shara, Marion, Kaye, Gow, Paul, Angus, Peter W

“…AIM: To determine characteristics and prognosticpredictors of patients with hepatocellular carcinoma(HCC) in association with non-alcoholic fatty liver…”
Get full text

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+) by Leroy, Vincent, Angus, Peter, Bronowicki, Jean‐Pierre, Dore, Gregory J., Hezode, Christophe, Pianko, Stephen, Pol, Stanislas, Stuart, Katherine, Tse, Edmund, McPhee, Fiona, Bhore, Rafia, Jimenez‐Exposito, Maria Jesus, Thompson, Alexander J.

“…Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced liver disease, are a challenging population in urgent need of…”
Get full text

Hepatopulmonary syndrome: Update on recent advances in pathophysiology, investigation, and treatment by Grace, Josephine A, Angus, Peter W

“…Hepatopulmonary syndrome (HPS) is an important cause of dyspnea and hypoxia in the setting of liver disease, occurring in 10–30% of patients with cirrhosis. It…”
Get full text

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial by Gane, Edward J, Dr, Roberts, Stuart K, MD, Stedman, Catherine AM, MD, Angus, Peter W, Prof, Ritchie, Brett, MD, Elston, Rob, PhD, Ipe, David, MS, Morcos, Peter N, PharmD, Baher, Linda, BS, Najera, Isabel, PhD, Chu, Tom, MD, Lopatin, Uri, MD, Berrey, M Michelle, MD, Bradford, William, MD, Laughlin, Mark, MD, Shulman, Nancy S, MD, Smith, Patrick F, PharmD

“…Summary Background Present interferon-based standard of care treatment for chronic hepatitis C virus (HCV) infection is limited by both efficacy and…”
Get full text

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial by Manns, Michael, Prof, Samuel, Didier, Prof, Gane, Edward J, Prof, Mutimer, David, Prof, McCaughan, Geoff, Prof, Buti, Maria, Prof, Prieto, MartÍn, MD, Calleja, José Luis, MD, Peck-Radosavljevic, Markus, Prof, Müllhaupt, Beat, Prof, Agarwal, Kosh, MD, Angus, Peter, Prof, Yoshida, Eric M, MD, Colombo, Massimo, Prof, Rizzetto, Mario, Prof, Dvory-Sobol, Hadas, PhD, Denning, Jill, MA, Arterburn, Sarah, MS, Pang, Phillip S, MD, Brainard, Diana, MD, McHutchison, John G, MD, Dufour, Jean-François, MD, Van Vlierberghe, Hans, Prof, van Hoek, Bart, Prof, Forns, Xavier, MD

“…Summary Background Treatment options are limited for patients infected by hepatitis C virus (HCV) with advanced liver disease. We assessed the safety and…”
Get full text

Risk stratification in acute upper GI bleeding: comparison of the AIMS65 score with the Glasgow-Blatchford and Rockall scoring systems by Robertson, Marcus, MBBS(Hons), Majumdar, Avik, MBBS(Hons), Boyapati, Ray, MBBS(Hons), Chung, William, MBBS, Worland, Tom, MBBS, Terbah, Ryma, MBBS, Wei, James, MBBS, Lontos, Steve, MBBS, MD, Angus, Peter, MBBS, MD, Vaughan, Rhys, MBBS, PhD

“…Background and Aims The American College of Gastroenterology recommends early risk stratification in patients presenting with upper GI bleeding (UGIB). The…”
Get full text

Regression of hepatocellular adenomas and systemic inflammatory syndrome after cessation of estrogen therapy by Sinclair, Marie, Schelleman, Anthony, Sandhu, Daljean, Angus, Peter W.

“…We report a case of dramatic systemic inflammatory symptoms and biochemical signs of inflammation related to multiple hepatic adenomas that completely resolved…”
Get full text

Use of Dual X‐ray Absorptiometry in men with advanced cirrhosis to predict sarcopenia‐associated mortality risk by Sinclair, Marie, Hoermann, Rudolf, Peterson, Adam, Testro, Adam, Angus, Peter W., Hey, Penelope, Chapman, Brooke, Gow, Paul J.

“…Introduction Reduced muscle area on CT scan is an independent predictor of mortality in cirrhosis. We examine for the first time the relationship between dual…”
Get full text

Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options by Grace, Josephine A, Herath, Chandana B, Mak, Kai Yan, Burrell, Louise M, Angus, Peter W

“…The RAS (renin-angiotensin system) is now recognized as an important regulator of liver fibrosis and portal pressure. Liver injury stimulates the hepatic…”
Get more information

Effect of Immunosuppressive Agents on Hepatocyte Apoptosis Post-Liver Transplantation by Lim, Eu Jin, Chin, Ruth, Nachbur, Ueli, Silke, John, Jia, Zhiyuan, Angus, Peter W, Torresi, Joseph

“…Immunosuppressants are used ubiquitously post-liver transplantation to prevent allograft rejection. However their effects on hepatocytes are unknown…”
Get full text

Activation of the Mas Receptor by Angiotensin-(1–7) in the Renin–Angiotensin System Mediates Mesenteric Vasodilatation in Cirrhosis by Grace, Josephine A, Klein, Sabine, Herath, Chandana B, Granzow, Michaela, Schierwagen, Robert, Masing, Noemi, Walther, Thomas, Sauerbruch, Tilman, Burrell, Louise M, Angus, Peter W, Trebicka, Jonel

“…Background & Aims Splanchnic vascular hypocontractility with subsequent increased portal venous inflow leads to portal hypertension. Although the…”
Get full text

Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD by Bruinstroop, Eveline, Dalan, Rinkoo, Cao, Yang, Bee, Yong Mong, Chandran, Kurumbian, Cho, Li Wei, Soh, Shui Boon, Teo, Eng Kiong, Toh, Sue-Anne, Leow, Melvin Khee Shing, Sinha, Rohit A, Sadananthan, Suresh Anand, Michael, Navin, Stapleton, Heather M, Leung, Christopher, Angus, Peter W, Patel, Sheila K, Burrell, Louise M, Lim, Su Chi, Sum, Chee Fang, Velan, S Sendhil, Yen, Paul M

“…Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and associated with significant morbidity and…”
Get full text

Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease by Leung, Christopher, Herath, Chandana B, Jia, Zhiyuan, Andrikopoulos, Sof, Brown, Bronwyn E, Davies, Michael J, Rivera, Leni R, Furness, John B, Forbes, Josephine M, Angus, Peter W

“…AIM To determine if manipulation of dietary advanced glycation end product(AGE), intake affects nonalcoholic fatty liver disease(NAFLD) progression and whether…”
Get full text